Read the full article here
Want to advertise or share your work with Science News Watch? Contact us.
Respiratory syncytial virus hospitalizes tens of thousands of people each year in the United States. Now there’s a powerful new tool against it: the first-ever RSV vaccine.
The U.S. Food and Drug Administration announced May 3 that it had granted approval for an RSV vaccine made by GlaxoSmithKline to be used in people 60 and older.
RSV is a respiratory virus that causes cold-like symptoms for many people, but can cause serious illness, hospitalization and death for infants and older people. In the United States, an estimated 60,000 to 160,000 older adults are hospitalized each year with lung infections caused by RSV, according to the U.S. Centers for Disease Control and Prevention. About 6,000 to 10,000 of them die from RSV infections each year. Older adults with chronic heart or lung disease, and those with weakened immune systems are especially vulnerable.
Founded in 2003, Science News Explores is a free, award-winning online publication dedicated to providing age-appropriate science news to learners, parents and educators. The publication, as well as Science News magazine, are published by the Society for Science, a nonprofit 501(c)(3) membership organization dedicated to public engagement in scientific research and education.
© 2023 Science News Watch - All Rights Reserved.
© 2023 Science News Watch - All Rights Reserved.